Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY

Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY

Source: 
Yahoo/Zacks.com
snippet: 

This week was relatively quiet for the pharma sector ahead of a string of earnings releases toward the end of this month. Glaxo GSK provided pipeline and regulatory updates on a couple of its two-drug HIV regimens. The FDA accepted Merck’s MRK regulatory application looking for a more flexible dosing option for its blockbuster PD-L1 inhibitor Keytruda and Sanofi’s SNY biologics license application (BLA) for multiple myeloma candidate isatuximab.